ReviewCancer drug resistance (Alhambra, Calif.)2022

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Amy H Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.